Innovative Medicines Initiative Launches 100th Project
The Innovative Medicines Initiative (IMI) has launched its 100th project in the form of Hypo-RESOLVE, a 4 year, EUR 26.8 million project on diabetes. The milestone comes as IMI celebrates its 10th anniversary with a series of events and activities. The IMI project portfolio is diverse; many projects, like Hypo-RESOLVE, focus on specific health issues such as diabetes, neurological conditions (including dementia, depression, and pain), cancer, auto-immune diseases (such as rheumatoid arthritis), and infectious diseases (including antimicrobial resistance and Ebola).
The European Commission is putting forward a set of measures to increase the availability of data in the EU, building on previous initiatives to boost the free flow of non-personal data in the Digital Single Market. Data-driven innovation is a key enabler of market growth, job creation, particularly for SMEs and startups, and the development of new technologies.